Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for.

United Therapeutics met analysts’ revenue expectations last quarter, reporting revenues of $735.9 million, up 19.7% year on year. It was a slower quarter for the company, with a slight miss of analysts’ EPS estimates.

Is United Therapeutics a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting United Therapeutics’s revenue to grow 7.7% year on year to $730 million, slowing from the 33.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $6.54 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. United Therapeutics has missed Wall Street’s revenue estimates twice over the last two years.

Looking at United Therapeutics’s peers in the biotechnology segment, some have already reported their Q1 results, giving us a hint as to what we can expect. AbbVie delivered year-on-year revenue growth of 8.4%, beating analysts’ expectations by 3.3%, and Gilead Sciences reported flat revenue, falling short of estimates by 2.1%. AbbVie traded up 6.6% following the results while Gilead Sciences was down 2.7%.

Read our full analysis of AbbVie’s results here and Gilead Sciences’s results here.

The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the biotechnology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5.2% on average over the last month. United Therapeutics is down 3.6% during the same time and is heading into earnings with an average analyst price target of $388.02 (compared to the current share price of $297.04).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.